GlassScriptPhysician profile
Sandra S Vexler
NPI 1285994384
$1,112.65
in general payments reported to CMS, 2019-2025
14 companies · $34.21 in 2025
The $34.21 reported for 2025 was less than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $224 · 2020: $14.40 · 2022: $159 · 2023: $436 · 2024: $245 · 2025: $34.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $714.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $383.58 | 2023-2024 | Caplyta |
| Alkermes, INC. | $144.20 | 2019-2024 | Lybalvi |
| Neurocrine Biosciences, INC. | $130.64 | 2022 | |
| Allergan, INC. | $115.09 | 2019 | |
| Inspire Medical Systems, INC. | $103.85 | 2023 | Inspire |
| Supernus Pharmaceuticals, INC. | $52.83 | 2022-2023 | Qelbree |
| Pfizer INC. | $43.88 | 2023 | |
| Corium, LLC | $34.21 | 2025 | Azstarys |
| Sunovion Pharmaceuticals INC. | $32.48 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.01 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $16.22 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.40 | 2020 | |
| Lundbeck LLC | $13.46 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Vexler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.